VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer

Surgery

Volumn 137, Issue 2, 2005, Pages 192-199

  Hotz, Hubert G ^a,b   Hines, O Joe ^a   Masood, Rizwan ^b   Hotz, Birgit ^a   Foitzik, Thomas ^c   Buhr, Heinz J ^c   Gill, Parkash S ^b   Reber, Howard A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Univ of S California Sch of Med   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; AUTOPSY; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN SECRETION; SURVIVAL; TUMOR VOLUME;

ANIMALS; ASCITES; BASE SEQUENCE; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; MICE, NUDE; MICROCIRCULATION; NEOPLASM TRANSPLANTATION; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PANCREATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 12944309305     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2004.07.015     Document Type: Article

References (35)

1. S.L. Parker, T. Long, S. Bolen, and P.A. Wingo Cancer statistics CA Cancer J Clin 47 1997 5 27
2. A.L. Warshaw, and C. Fernandez-del Castillo Pancreatic carcinoma N Engl J Med 326 1992 455 465
3. C.J. Yeo, and J.L. Cameron Pancreatic cancer Cur Probl Surg 36 2 1999 59 152
4. M. Trede, H.D. Saeger, G. Schwall, and B. Rumstadt Resection of pancreatic cancer: surgical achievements Langenbeck's Arch Surg 383 1998 121 128
5. B. Glimelius Chemotherapy in the treatment of cancer of the pancreas J Hepatobiliary Pancreat Surg 5 1999 235 241
6. J.H. Klinkenbijl, J. Jeekel, T. Sahmoud, R. van Pel, M.L. Couvreur, and C.H. Veenhof Adjuvant radiotherapy and 5-fluoruracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group Ann Surg 230 1999 776 782
7. L. Rosenberg Pancreatic cancer: a review of emerging therapies Drugs 59 2000 1071 1089
8. J. Folkman Angiogenesis in cancer, vascular, rheumatoid, and other disease Nat Med 1 1995 27 31
9. J.M. Brown, and A.J. Giaccia The unique physiology of solid tumors: opportunities (and problems) for cancer therapy Cancer Res 58 1998 1408 1416
10. G. Neufeld, T. Cohen, S. Gengrinovitch, and Z. Poltorak Vascular endothelial growth factor (VEGF) and its receptors FASEB J 13 1999 9 22
11. T. Veikkola, M. Karkkainen, L. Claesson-Welsh, and K. Alitalo Regulation of angiogenesis via vascular endothelial growth factor receptors Cancer Res 60 2000 203 212
12. J. Itakura, T. Ishiwata, H. Friess, H. Fujii, Y. Matsumoto, and M.W. Buechler Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression Clin Cancer Res 3 1997 1309 1316
13. R. Kuehn, P.I. Lelkes, C. Bloechle, A. Niendorf, and J.R. Izbicki Angiogenesis, angiogenic growth factors, and cell adhesion molecules are upregulated in chronic pancreatic diseases: angiogenesis in chronic pancreatitis and in pancreatic cancer Pancreas 18 1999 96 103
14. J. Itakura, T. Ishiwata, B. Shen, M. Kornmann, and M. Korc Concomitant overexpression of vascular endothelial growth factor and its receptors in pancreatic cancer Int J Cancer 85 2000 27 34
15. Y. Seo, H. Baba, T. Fukuda, M. Takashima, and K. Sugimachi High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma Cancer 88 2000 2239 2245
16. N. Ikeda, M. Adachi, T. Taki, C. Huang, H. Hashida, and A. Takabayashi Prognostic significance of angiogenesis in human pancreatic cancer Br J Cancer 79 1999 1553 1563
17. J. Drevs, I. Hofmann, H. Hugenschmidt, C. Wittig, H. Madjar, and M. Muller Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor growth, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model Cancer Res 60 2000 4819 4824
18. S.R. Wedge, D.J. Ogilvie, M. Dukes, J. Kendrew, J.O. Curwen, and L.F. Hennequin ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy Cancer Res 60 2000 970 975
19. R.A. Brekken, J.P. Overholser, V.A. Stastny, J. Waltenberger, J.D. Minna, and P.E. Thorpe Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice Cancer Res 60 2000 5117 5124
20. A. Vitaliti, M. Wittmer, R. Steiner, L. Wyder, D. Neri, and R. Klemenz Inhibition of tumor angiogenesis by a single-chain antibody directed against vascular endothelial growth factor Cancer Res 60 2000 4311 4314
21. R. Masood, J. Cai, T. Zheng, D.L. Smith, Y. Naidu, and P.S. Gill Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi's sarcoma Proc Nat Acad Sci 94 1997 979 984
22. M.H. Tan, T. Shimano, and T.M. Chu Differential localization of human pancreatic cancer-associated antigen and carcinoembryogenic antigen in homologous pancreatic tumoral xenograft J Natl Cancer Inst 67 1981 563 566
23. R.S. Metzgar, M.T. Gaillard, S.J. Levine, F.L. Tuck, E.H. Bossen, and M.J. Borowitz Antigens of human pancreatic adenocarcinoma cells defined by murine monoclonal antibodies Cancer Res 42 1982 601 608
24. H.G. Hotz, H.A. Reber, B. Hotz, P.C. Sanghavi, T. Yu, and T. Foitzik Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth J Gastrointest Surg 5 2001 131 138
25. H.G. Hotz, O.J. Hines, T. Foitzik, and H.A. Reber Animal models of exocrine pancreatic cancer Int J Colorectal Dis 15 2000 136 143
26. N. Weidner Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors Breast Cancer Res Treat 36 1995 169 180
27. N. Weidner Intratumor microvessel density as a prognostic factor in cancer Am J Pathol 147 1995 9 19
28. N. Liu, T. Furukawa, M. Kobari, and M.-S. Tsao Comparative phenotypic studies of duct epithelial cells line derived from normal human pancreas and pancreatic carcinoma Am J Pathol 153 1998 263 269
29. H.G. Hotz, O.J. Hines, B. Hotz, T. Yu, P. Buechler, and H.A. Reber Anti-angiogenic therapy for pancreatic cancer: the effect of a neutralizing anti-VEGF antibody in vitro and in vivo Pancreas 19 1999 424
30. H.G. Hotz, O.J. Hines, H.A. Reber, T. Foitzik, and H.J. Buhr Anti-angiogenic therapy with a neutralizing anti-VEGF antibody reduces tumor size and metastasis in an orthotopic model of pancreatic cancer A. Encke Chirurgisches Forum 2000 fuer experimentelle und klinische Forschung 2000 Springer-Verlag Heidelberg 85 88
31. M. Prewett, J. Huber, Y. Li, A. Santiago, W. O'Connor, and K. King Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors Cancer Res 59 1999 5209 5218
32. R.M. Hoffman Orthotopic is orthodox: why are orthotopic-transplant metastatic models different from all other models? J Cell Biochem 56 1994 1 3
33. T. Kubota Metastatic models of human cancer xenografted in the nude mouse: the importance of orthotopic transplantation J Cell Biochem 56 1994 4 8
34. H.F. Dvorak, J.A. Nagy, D. Feng, L.F. Brown, and A.M. Dvorak Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis Curr Top Microbiol Immunol 237 1999 97 132
35. J.A. Nagy, E.M. Masse, K.T. Herzberg, M.S. Meyers, K.T. Yeo, and T.K. Yeo Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation Cancer Res 55 1995 360 368